One drug, five cancers: trial aims to widen use of promising treatment
NCT ID NCT07192068
Summary
This study is testing whether an existing cancer drug called zanidatamab can help treat several different types of advanced solid tumors that share a specific genetic alteration in the HER2 gene. The trial will enroll 105 adults with advanced endometrial, colorectal, head & neck, non-small cell lung cancer, or sarcoma who have run out of standard treatment options. Participants will receive the drug by IV every three weeks for as long as it helps control their cancer, with regular scans to check its effect.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Chu Timone
RECRUITINGMarseille, France
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de Lorraine
ACTIVE_NOT_RECRUITINGVandœuvre-lès-Nancy, France
-
Institut de Cancérologie de l'Ouest
ACTIVE_NOT_RECRUITINGAngers, France
Conditions
Explore the condition pages connected to this study.